Poly Medicure gains 6% on successful fund raising via QIP issue

The company's QIP committee approved the allotment of 7.63 million equity shares to eligible qualified institutional buyers at a price of Rs 524 per equity share

Stock broker, broker, trader, market, markets, stock markets, stocks
SI Reporter Mumbai
2 min read Last Updated : Feb 19 2021 | 1:38 PM IST
Shares of medical equipment maker Poly Medicure rose 6 per cent to hit a new high of Rs 689 on the BSE in Friday’s intra-day trade after the company successfully raised Rs 400 crore through qualified institutional placement (QIP) route. In the past one week, the stock has rallied 16 per cent, as compared to a nearly 1 per cent decline in the S&P BSE Sensex.

“The QIP opened on February 15, 2021, and closed on February I 8, 2021,” Poly Medicure said in a regulatory filing. 

On Thursday, the company’s QIP committee approved the allotment of 7.63 million equity shares to eligible qualified institutional buyers at a price of Rs 524 per equity share, including a premium of Rs 519 per share, which was at a discount of Rs 26.79 (4.86 per cent to the floor price of Rs 550.79 per share), it said.

The company proposed to utilise the net proceeds for funding suitable organic and inorganic growth opportunities, ongoing capital expenditure, other long term and short terms requirements, pre-payment and/or repayment of outstanding borrowings and general corporate purpose.

Poly Medicure is among the top five companies in the medical devices industry in India, in terms of operating income and profitability margin performance, in fiscal 2019. 
 
The company manufactures and supplies, in India and internationally, a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anaesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others.

The management said as an established player of significant scale, Polymed is set to benefit from the various tailwinds in the Indian market. Polymed’s strong pipeline is key to further profitably. The high brand equity and existing customer and distributor relationships are key for tapping into emerging growth opportunities, the company said in a presentation.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Poly MedicureBuzzing stocksQIPMarketsfund raisingNews

Next Story